Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors

被引:10
作者
Ho, GD [1 ]
Silverman, L [1 ]
Bercovici, A [1 ]
Puchalski, C [1 ]
Tulshian, D [1 ]
Xia, Y [1 ]
Czarniecki, M [1 ]
Green, M [1 ]
Cleven, R [1 ]
Zhang, HT [1 ]
Fawzi, A [1 ]
机构
[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
关键词
D O I
10.1016/S0960-894X(98)00681-7
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Syntheses and structure-activity relationships (SAR) of cGMP selective phosphodiesterase inhibitors are discussed. Potent and selective inhibitors are produced when the C-2 position of tetracyclic guanine 1 is substituted with alkyl chains containing six carbon atoms, (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:7 / 12
页数:6
相关论文
共 7 条
  • [1] AHN HS, 1992, ADV SEC MESS PHOSPH, V25, P271
  • [2] AHN HS, 1989, BIOCHEM PHARMACOL, V38, P3331
  • [3] Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity
    Ahn, HS
    Bercovici, A
    Boykow, G
    Bronnenkant, A
    Chackalamannil, S
    Chow, J
    Cleven, R
    Cook, J
    Czarniecki, M
    Domalski, C
    Fawzi, A
    Green, M
    Gundes, A
    Ho, G
    Laudicina, M
    Lindo, N
    Ma, K
    Manna, M
    McKittrick, B
    Mirzai, B
    Nechuta, T
    Neustadt, B
    Puchalski, C
    Pula, K
    Silverman, L
    Smith, E
    Stamford, A
    Tedesco, RP
    Tsai, HG
    Tulshian, D
    Vaccaro, H
    Watkins, RW
    Weng, XY
    Witkowski, JT
    Xia, Y
    Zhang, HT
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (14) : 2196 - 2210
  • [4] CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES - FUNCTIONAL IMPLICATIONS OF MULTIPLE ISOFORMS
    BEAVO, JA
    [J]. PHYSIOLOGICAL REVIEWS, 1995, 75 (04) : 725 - 748
  • [5] NEUSTADT BN, 1990, Patent No. 9119717
  • [6] A CONVENIENT METHOD FOR OBTAINING TRANS-2-AMINOCYCLOHEXANOL AND TRANS-2-AMINOCYCLOPENTANOL IN ENANTIOMERICALLY PURE FORM
    OVERMAN, LE
    SUGAI, S
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1985, 50 (21) : 4154 - 4155
  • [7] Sybertz E., 1995, CURR PHARM DESIGN, V1, P373